Department of Anesthesia, Pain Management and Perioperative Medicine, Dalhousie University, Halifax, Canada.
Department of Pharmacology, and Dalhousie University, Halifax, Canada.
Cannabis Cannabinoid Res. 2021 Aug;6(4):327-339. doi: 10.1089/can.2020.0130. Epub 2021 Mar 3.
Acute central nervous system (CNS) injury, such as stroke, spinal cord injury, or traumatic brain injury can result in dysregulated immune response, and the condition is known as CNS injury-induced immunodeficiency syndrome (CIDS). The endocannabinoid system is an important homeostatic regulator in the CNS and immune system. Activation of cannabinoid 2 receptors (CB2R) on immune cells has been reported to dampen inflammation, suggesting a potential role of CB2R in the peripheral immune response following CNS injury. In this study, we have investigated the effect of CB2R modulation on the peripheral immune response during CIDS. Experimental CNS injury was induced in C57BL/6 mice through intracerebral injection of the vasopressor peptide, endothelin-1. A selective CB2R agonist (HU308) was used as an early treatment before the onset of CIDS and AM630, a selective CB2R antagonist, was administered as a later-phase therapy to combat the systemic immunodeficiency following the CNS injury. The peripheral immune response to endotoxin was studied 24 h after the CNS injury using intravital microscopy to examine leukocyte activation within the intestinal microcirculation in mice. Brain infarct size, and plasma levels of cytokines and soluble adhesion molecules were measured as additional parameters for the assessment of treatment outcomes. Our results showed that early CB2R activation with HU308 reduced brain injury size and restored leukocyte response to endotoxin in the peripheral microcirculation. Late CB2R inhibition with AM630 also improved the peripheral leukocyte response to endotoxin and did not exacerbate the extent of brain injury. CB2R activation has the potential to mitigate CNS injury as an early treatment by limiting neuroinflammation and preventing the development of CIDS. At the later stage with already-established CIDS, treatment may require dampening CB2R activation to improve the patient's outcome.
急性中枢神经系统 (CNS) 损伤,如中风、脊髓损伤或创伤性脑损伤,可导致免疫调节异常,这种情况被称为 CNS 损伤诱导的免疫缺陷综合征 (CIDS)。内源性大麻素系统是 CNS 和免疫系统中的重要内稳态调节剂。已有报道称,免疫细胞上的大麻素 2 型受体 (CB2R) 的激活可抑制炎症,提示 CB2R 在 CNS 损伤后外周免疫反应中可能发挥作用。在这项研究中,我们研究了 CB2R 调节对 CIDS 期间外周免疫反应的影响。通过向 C57BL/6 小鼠脑内注射血管加压肽内皮素-1 诱导实验性 CNS 损伤。使用选择性 CB2R 激动剂 (HU308) 在 CIDS 发作前进行早期治疗,并用选择性 CB2R 拮抗剂 AM630 进行后期治疗,以对抗 CNS 损伤后的全身性免疫缺陷。使用活体显微镜研究 CNS 损伤后 24 小时对脂多糖的外周免疫反应,以检查小鼠肠道微循环中的白细胞激活。还测量了脑梗死面积以及血浆细胞因子和可溶性黏附分子的水平,作为评估治疗结果的附加参数。我们的结果表明,早期使用 HU308 激活 CB2R 可减少脑损伤的大小,并恢复外周微循环中白细胞对脂多糖的反应。晚期使用 AM630 抑制 CB2R 也改善了外周白细胞对脂多糖的反应,并且不会加重脑损伤的程度。CB2R 激活具有作为早期治疗的潜力,通过限制神经炎症和防止 CIDS 的发展来减轻 CNS 损伤。在已经建立的 CIDS 的后期阶段,治疗可能需要抑制 CB2R 的激活以改善患者的预后。